Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21516

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Kidney Transplant
Interventions: eGFR reporting; Diagnostic Test
Lead sponsor: Martina McGrath, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 67
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 49 more

Conditions: Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 149
States / cities: Berkeley, California • Irvine, California • Orange, California + 122 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Encinitas, California • Encino, California + 32 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200, Cetrelimab; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: JNJ-90301900, Cisplatin, Intensity Modulated Radiation Therapy (IMRT), Carboplatin, Paclitaxel; Drug · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 7 more

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 150
States / cities: Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more

Conditions: Cognition, Cardiometabolic Risk Factors, Life Satisfaction
Interventions: Pistachio-enriched diet, Usual diet; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cystic Lesions
Interventions: Not listed
Lead sponsor: Amplified Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • New Brunswick, New Jersey

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus, Samuraciclib, PH FDC SC, Palbociclib, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Duarte, California • Irvine, California • San Francisco, California + 9 more

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial of Pistachio Consumption in Older Adults

A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer